Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer - PubMed (original) (raw)
. 2003 Oct 15;9(13):4935-43.
Affiliations
- PMID: 14581368
Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer
Shashi R Harvey et al. Clin Cancer Res. 2003.
Abstract
Purpose: Pancreatic cancer remains a devastating problem with the majority of patients succumbing to death from this disease. A hallmark of pancreatic cancer is the loss of basement membrane that may be attributed to the action of urinary plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9). These enzymes are also implicated in angiogenesis. uPA and microvessel density have been shown to be good prognostic indicators for breast and colon cancer. MMP-9 and microvessel density have not been investigated in pancreatic cancer. We have therefore investigated by immunohistochemistry: (a) frequency of uPA expression and its receptor uPAR and the site of synthesis of uPA by in situ hybridization (ISH); (b) MMP-9 and its coexpression with uPA; (c) microvessel density as determined by von Willebrand factor staining and its relationship to uPA and MMP-9 expression; and (d) correlation of these parameters with survival.
Experimental design: Archival paraffin sections of 27 pancreatic tumors were semiquantitatively investigated by immunohistochemistry using the following antibodies: (a) monoclonal antibodies (MAbs) uPA(1) and uPA(2) (3689 and 394, respectively); (b) MAb uPAR, (no. 3932); (c) MAb MMP-9 (no. 936); and (d) rabbit anti-F8RA/vWF. ISH was performed using a uPA cDNA.
Results: Both uPA antibodies revealed overexpression of uPA (93%) often with uniform staining of tumor cells. uPAR and MMP-9 showed focal staining in only 52 and 37% of tumors, respectively. Morphologically normal appearing ductal cells in close proximity to tumors overexpressed uPA in contrast to distally located normal cells (P = <0.001). uPA staining was also investigated in pancreatic intraepithelial neoplasia (PanIN) lesions. PanIN 1A/B staining for uPA was seen in 8 cases (30%), that for PanIN 2 in 19 cases (70%), and for PanIN3 in 12 cases (44%). Lumen of microvessels in the tumor stroma also revealed staining of uPA in 10 cases (37%). ISH experiments revealed the presence of uPA mRNA not only in the cytoplasm of tumor cells but also in adjacent normal appearing ducts as well as in PanIN lesions. Patients with overexpression of uPA, uPAR, or MMP-9 had a trend toward poorer survival than those who did not express it. Microvessel density did not show any significant relationship with uPA, uPAR, and MMP-9 expression and survival.
Conclusions: We conclude that uPA and MMP-9 are potential prognostic indicators in pancreatic cancer, whereas microvessel density may not be one. This study confirms our previous observation that uPA is made by the tumor cells themselves. Presence of uPA in vessels of tumor stroma suggests that uPA is in circulation, and its measurement and that of MMP-9 in the blood of these patients may aid in prognosis. Patients showing overexpression of uPA and MMP-9 have a trend toward shorter survival time.
Similar articles
- Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L, Madigan MC, Chen H, Liu F, Patterson KI, Beretov J, O'Brien PM, Li Y. Wang L, et al. Gynecol Oncol. 2009 Aug;114(2):265-72. doi: 10.1016/j.ygyno.2009.04.031. Epub 2009 May 17. Gynecol Oncol. 2009. PMID: 19450871 - The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R, Schaaf A. Hildenbrand R, et al. Int J Oncol. 2009 Jan;34(1):15-23. Int J Oncol. 2009. PMID: 19082473 - Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
He Y, Liu XD, Chen ZY, Zhu J, Xiong Y, Li K, Dong JH, Li X. He Y, et al. Clin Cancer Res. 2007 Jun 1;13(11):3115-24. doi: 10.1158/1078-0432.CCR-06-2088. Clin Cancer Res. 2007. PMID: 17545513 - Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells.
de Geus SW, Baart VM, Boonstra MC, Kuppen PJ, Prevoo HA, Mazar AP, Bonsing BA, Morreau H, van de Velde CJ, Vahrmeijer AL, Sier CF. de Geus SW, et al. Biomark Insights. 2017 Jun 22;12:1177271917715443. doi: 10.1177/1177271917715443. eCollection 2017. Biomark Insights. 2017. PMID: 28690396 Free PMC article. Review. - Molecular prognostic markers in pancreatic cancer: a systematic review.
Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP. Garcea G, et al. Eur J Cancer. 2005 Oct;41(15):2213-36. doi: 10.1016/j.ejca.2005.04.044. Epub 2005 Sep 16. Eur J Cancer. 2005. PMID: 16146690 Review.
Cited by
- Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.
Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH. Wang Z, et al. Cancer Res. 2009 Mar 15;69(6):2400-7. doi: 10.1158/0008-5472.CAN-08-4312. Epub 2009 Mar 10. Cancer Res. 2009. PMID: 19276344 Free PMC article. - Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer.
McCarroll J, Teo J, Boyer C, Goldstein D, Kavallaris M, Phillips PA. McCarroll J, et al. Front Physiol. 2014 Jan 24;5:2. doi: 10.3389/fphys.2014.00002. eCollection 2014. Front Physiol. 2014. PMID: 24478715 Free PMC article. Review. - IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.
Zhou H, Qian W, Uckun FM, Wang L, Wang YA, Chen H, Kooby D, Yu Q, Lipowska M, Staley CA, Mao H, Yang L. Zhou H, et al. ACS Nano. 2015 Aug 25;9(8):7976-91. doi: 10.1021/acsnano.5b01288. Epub 2015 Aug 10. ACS Nano. 2015. PMID: 26242412 Free PMC article. - High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma.
Loosen SH, Tacke F, Püthe N, Binneboesel M, Wiltberger G, Alizai PH, Kather JN, Paffenholz P, Ritz T, Koch A, Bergmann F, Trautwein C, Longerich T, Roderburg C, Neumann UP, Luedde T. Loosen SH, et al. Carcinogenesis. 2019 Aug 22;40(8):947-955. doi: 10.1093/carcin/bgz033. Carcinogenesis. 2019. PMID: 30805627 Free PMC article. - Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer.
Langers AM, Verspaget HW, Hommes DW, Sier CF. Langers AM, et al. World J Gastrointest Oncol. 2011 Jun 15;3(6):79-98. doi: 10.4251/wjgo.v3.i6.79. World J Gastrointest Oncol. 2011. PMID: 21731908 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous